Monopar Therapeutics
Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.
$111.89
After-hours close−0.50 (−0.44%)
At close$112.39(−1.36%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 93.09%6.24M sharesInsiders 3.86%258.3K sharesOther 3.05%204.8K shares
Shares outstanding 6.70M · Float 4.16M · 62.2% free float
Institutions13F, as of Mar 31, 2026
82 holders · 6.24M shares · 21 new positions · 53 increased · 18 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 1.32M | 19.67% | 0 | May 18, 2026 |
| Ra Capital Management, L.P. | 667.2K | 9.96% | 0 | May 15, 2026 |
| Saturn V Capital Management LLC | 345.6K | 5.16% | +19.9K | May 15, 2026 |
| Deerfield Management Company, L.P. (Series C) | 323.7K | 4.83% | +153.2K | May 15, 2026 |
| BlackRock, Inc. | 316.6K | 4.73% | +61.7K | May 13, 2026 |
| Adage Capital Partners GP, L.L.C. | 309.2K | 4.62% | −330.3K | May 15, 2026 |
| Siren, L.L.C. | 270.1K | 4.03% | +57.8K | May 14, 2026 |
| Adar1 Capital Management, LLC | 264.3K | 3.95% | +30.4K | May 18, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 19.50% | 1.29M | 13G | Nov 14, 2025 ↗ |
| Ein # | 10.90% | 562.5K | Nov 6, 2024 ↗ | |
| RA Capital Management, L.P. | 9.90% | 667.6K | 13G | Feb 17, 2026 ↗ |
| Alexion Pharmaceuticals, Inc.incl. AstraZeneca PLC | 9.90% | 387.3K | 13G | Oct 28, 2024 ↗ |
| Peter Kolchinskyincl. Rajeev Shah, RA Capital Management, L.P. +1 more | 9.70% | 511.2K | 13G | Oct 31, 2024 ↗ |
| AstraZeneca PLC | 7.80% | 522.7K | 13G | Feb 6, 2026 ↗ |
| Adage Capital Management, L.P. | 6.23% | 424.2K | 13G | May 13, 2026 ↗ |
| Saturn V Capital Management LP | 5.20% | 345.6K | 13G | May 15, 2026 ↗ |
| Tang Capital Management, LLC | 5.10% | 200.0K | Oct 24, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Hendricks Diane | 10 percent owner | 567.6K | 8.47% | Dec 17, 2025 |
| Tactic Pharma LLC | 10 percent owner | 272.0K | 4.06% | Sep 26, 2025 |
| Chandler Robinson | director, officer: Chief Executive Officer | 162.1K | 2.42% | Jul 2, 2026 |
| Andrew Cittadine | officer: Chief Operating Officer | 55.6K | 0.83% | Jul 2, 2026 |
| Lavina Talukdar | director | 14.0K | 0.21% | Mar 6, 2025 |
| Arthur J. Klausner | director | 8.8K | 0.13% | Dec 19, 2025 |
| Raymond Anderson | director | 5.4K | 0.08% | Aug 28, 2026 |
| Christopher M. Starr | director | 5.2K | 0.08% | Jul 16, 2025 |
| Patrice Rioux | other: Acting Chief Medical Officer | 5.1K | 0.08% | Aug 27, 2026 |
| Quan Anh Vu | officer: Chief Financial Officer | 2.2K | 0.03% | Jul 2, 2026 |
4 ten-percent owners hold 1.45M shares by Form 4, outside the officers-and-directors figure above · 3 people have not refiled in the last 18 months (53.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Kim R. Tsuchimotodirector | Sale · 6 lots | 4,090 | $111.39 | 0 |
| Aug 25, 2026 | Raymond Andersondirector | Sale · 4 lots | 3,788 | $111.65 | 5,373 |
| Aug 26, 2026 | Patrice Riouxother: Acting Chief Medical Officer | Sale | 1 | $111.26 | 5,065 |
| Dec 26, 2025 | Quan Anh Vuofficer: Chief Financial Officer | Purchase | 1,500 | $69.95 | 1,500 |
| Dec 18, 2025 | Arthur J. Klausnerdirector | Sale · 2 lots | 5,121 | $67.15 | 8,762 |
| Sep 24, 2025 | Tactic Pharma LLC10 percent owner | Sale | 550,229 | $63.61 | 272,026 |
CongressHouse and Senate disclosures
Not reported.